Study of EZN-2208 Pediatric Patients With Solid Tumors
Status: | Archived |
---|---|
Conditions: | Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | Any |
Updated: | 7/1/2011 |
Start Date: | February 2010 |
A Phase 1/2 Study of EZN-2208 in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors
The goal of this clinical research study is to find the highest tolerable dose of EZN-2208
that can be given to pediatric patients with Relapsed or Refractory Solid Tumors. The safety
of the study drug and its effect on the disease will also be studied.
Pharmacokinetic (PK) testing of EZN-2208, will be perfomed for patients who volunteer. PK
testing measures the amount of a drug in the body at different time points.
We found this trial at
2
sites
850 Boylston Street
Chestnut Hill, Massachusetts 02467
Chestnut Hill, Massachusetts 02467
1-800-BWH-9999
Brigham & Women's Hospital Women's Health Center At Brigham and Women
Click here to add this to my saved trials